


FACT SHEET

Large-scale antibody production: Hybridoma or recombinant?

After successful identification of a unique hybridoma for your therapeutic or diagnostic program, you need to quickly generate gram quantities for further evaluation. Here is the critical question:

What is the best production strategy?





Comparison of key performance features

Features	Hybridoma	Transient TunaCHO™ platform
Expression level	10-50 mg/L	100-500 mg/L
Scale to reach 1 gram quantity	20-100 L	2–10 L
Cost	\$\$\$	\$\$
Timeline	4–6 months*	3-4 months**
Batch-to-batch consistency	Low	High
Security of long-term supply	Unstable	Stable
Pathway to GMP production	Difficult	Straightforward
Sequence verification	Not always. Lack of protection	Yes. Early patent protection

Hybridoma timeline estimates include cell line recovery, cell culture optimization, pilot production, and large-scale production

The choice is clear: go with Curia's TunaCHO[™] transient production platform!

To learn more, visit curiaglobal.com/biologics

Solutions developed by Curia



^{**}Transient recombinant TunaCHO timeline estimates include hybridoma sequencing, gene synthesis and cloning, pilot production, and large-scale production